MetaCap

Bicara Therapeutics (BCAX) vs Crescent Biopharma (CBIO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Crescent Biopharma (CBIO) has outperformed Bicara Therapeutics (BCAX) over the past year, losing 0.5% versus a loss of 53.2%. Bicara Therapeutics is the larger company by market cap ($560.3 million vs $543.2 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BCAX-53.22%CBIO-0.46%
+115%+25%-64%
Nov 21, 20251 yearNov 20, 2026
BCAX-63.95%CBIO-23.53%
+158%+42%-74%
Sep 9, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BCAX versus CBIO key metrics
MetricBCAXCBIO
Share price$8.44$13.00
Market cap$560.31M$543.21M
1-day change-7.46%+0.70%
YTD return-49.85%+9.61%
1-year return-53.22%-0.46%
5-year return—-92.74%
EPS (TTM)$-3.46$-7.29
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$10.84M
Net income (latest FY)$-137.95M$-153.94M
Operating margin—-1407.52%
Net margin—-1419.61%
52-week high$30.99$27.41
52-week low$7.87$8.72
Distance from 52-week high-72.77%-52.57%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+281.16%+148.69%
Average volume1.20M361.17K
Shares outstanding66.39M38.90M
Employees10380
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • CBIO has outperformed BCAX by 52.8 percentage points over the past year.

About Bicara Therapeutics

BCAX stock →

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 103 employees

About Crescent Biopharma

CBIO stock →

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.

Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees

BCAX vs CBIO FAQ

Which is bigger, Bicara Therapeutics or Crescent Biopharma?

Bicara Therapeutics (BCAX) is larger, with a market capitalization of $560.31M compared with $543.21M for Crescent Biopharma (CBIO).

Which stock has performed better over the past year, BCAX or CBIO?

CBIO returned -0.46% over the past 12 months, compared with -53.22% for BCAX (price return, excluding dividends). Past performance does not predict future results.

Are Bicara Therapeutics and Crescent Biopharma in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons